|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Mounting evidence has demonstrated that PPM1D participates in the development and progression of a wide variety of tumors.
|
30374621 |
2020 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Furthermore, high expression levels of Wip1 were significantly associated with increasing tumor size (P=0.002), pathological grade (P=0.025), clinical T stage (P=0.001) and lymph nodal metastasis (P=0.003).
|
28356972 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Wild-type p53-induced phosphatase (Wip1), a member of the 2C type serine/threonine protein phosphatase family, is closely associated with the p53 gene, which is the most important tumor-suppressor gene.
|
28781635 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Most importantly, Wip1 down-regulation impaired tumor migration capacity of ICC cells <i>in vivo</i>.
|
28915621 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Taken together, the inhibition of Wip1 might fortify p53-mediated tumor suppression by Mdm2 antagonists.
|
27183917 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We have found that a treatment with a low dose (75 nM) of MK-1775, a recently described specific chemical inhibitor of Wee1, decreases CDDP-induced H2AX phosphorylation in p53-negative cells and enhances the Wip1-sensitization of p53-negative tumors.
|
27077811 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We found that the mean mRNA expression of PPM1D is higher in WHO grade II and III meningiomas than in grade I tumors.
|
26942600 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
As a well-defined oncogene, wild-type p53-induced phosphatase 1 (WIP1) plays an inhibitory role in several tumor suppressor pathways, including p53.
|
25888625 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, Wip1 could be an important factor that contributes to tumor heterogeneity, suggesting that its inhibition may decrease the rate of cancer evolution.
|
25381821 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Wip1 expression deletion determines independent risk factors for prognosis of patients with nasopharyngeal carcinoma in addition to tumor T stage, clinical stage, histological grade and lymph node metastasis outside by Cox-2 in the regression analysis (P < 0.05). qRT-PCR and Western blot showed that CNE2 cell transfected Wip1 siRNA had a lower relative expressive content than normal cell (P < 0.05).
|
25060857 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The high expression of PPM1D in NSCLC tissues was significantly correlated with tumor grade (P = 0.006), tumor size (P = 0.017), clinical stage (P = 0.001), and lymph node metastases (P = 0.002).
|
25412952 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We examined WIP1 mRNA levels across multiple tumor types and found the highest levels in breast cancer, leukemia, medulloblastoma and neuroblastoma.
|
25658463 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The WIP1 oncogene is overexpressed in Group 3 and 4 tumors, which contain medulloblastomas with the most aggressive clinical behavior.
|
24632620 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Wip1- negative patients had a higher tumor-free/overall survival rate than patients with high Wip1 expression (P = 0.001, P = 0.002 respectively).
|
25334029 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
However, there were significant differences between Wip1 expression and lymph node metastasis, clinical stages, and tumor differentiation (P < 0.05).
|
24272082 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
As a result, using a pharmacological inhibitor of Wip1 has been suggested to be a novel chemotherapeutic approach to recover the innate tumor surveillance in a variety of cancers.
|
24126074 |
2014 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Remarkably, mutations in PPM1D are present not only in the tumors but also in other tissues of breast and colorectal cancer patients, indicating that they arise early in development or affect the germline.
|
23649806 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The level of Wip1 protein expression was not correlated with age, gender, or tumor site, but appeared linked with lymph node metastasis, Dukes stage, histological grade, and liver metastasis.
|
23679302 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We also find a role contributed by the cellular Wip1 phosphatase protein in tumor formation in Tax transgenic mice.
|
23256545 |
2012 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Overexpression of Wip1 is observed in certain types of human tumors that are associated with significantly poor prognosis.
|
22325093 |
2012 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The Wip1 gene is frequently amplified or overexpressed in human cancers, promoting tumor growth by switching off major checkpoint kinases and p53.
|
22405851 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In recent years, analysis of Wip1 has focused primarily on its role in tumorigenesis because of its overexpression in human tumors and a profound tumor-resistant phenotype of Wip1-deficient mice.
|
22340722 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The PPM1D gene encodes a serine threonine phosphatase, which is involved in the regulation of several tumour suppressor pathways, including the p53 pathway.
|
20543821 |
2010 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The PP2C family serine/threonine phosphatase WIP1 is characterized by distinctive oncogenic properties mediated by inhibitory functions on several tumor suppressor pathways, including ATM, CHK2, p38MAPK and p53.
|
19879149 |
2010 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Here, we report that the wild-type p53-induced phosphatase 1 (Wip1) phosphatase, which is often overexpressed in a variety of tumors, effectively dephosphorylates gamma-H2AX in vitro and in vivo.
|
20460517 |
2010 |